The MCF-7 cell line was derived from a patient with metastatic breast cancer in 1970. Since then it has become a prominent model system for the study of estrogen receptor-positive breast cancer. With this model as a focus, this review summarizes important studies addressing tumor necrosis factor-α as a prototypical apoptosis-inducing cytokine in MCF-7 cells. Both survival and death receptor signaling pathways are discussed in terms of their role in chemotherapy-induced apoptosis as well as in chemoresistance. Novel therapeutic approaches to the treatment of breast cancer are proposed utilizing knowledge of these signaling pathways as targets. Specifically, ceramide metabolism is proposed as a novel target for chemosensitivity, perhaps combined with selective inhibitors of Bcl-2 or PI3K/Akt/nuclear factor-κB. Suggested areas of future research include translational studies manipulating candidate survival and death signaling pathways.
GoldsteinLJ, CianfroccaM, von MehrenM, GradelT, KilpatrickD, VadersL, Smolenski-BurkeS, BradyD, VogelL. Breast cancer research. Fox Chase Cancer Center Scientific Report. Philadelphia: Fox Chase Cancer Center, pp 158162, 2000.
2.
RussoJ, YangX, HuY, BoveB, HuangY, SilvaIDCG, TahinQ, WuY, HiggyN, ZekriA, RussoI. Biological and molecular basis of human breast cancer. Frontiers Biosci3: d944d960, 1998.
3.
ParkinDM, PisaniP, FerlayJ. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer54: 594606, 1993.
4.
American Cancer Society.Cancer Facts and Figures. American Cancer Society, Atlanta, GA, 1996.
5.
WuJ. Apoptosis and angiogenesis: two promising tumor markers in breast cancer (review). Anticancer Res16: 22332240, 1996.
6.
FurthPA. Apoptosis and the development of breast cancer. In: BowcockAM, Ed. Breast Cancer: Molecular Genetics, Pathogenesis, and Therapeutics. New Jersey: Humana Press, pp 171180, 1999.
7.
DebatinA-K. Activation of apoptosis pathways by anticancer treatment. Toxicol Lett112-113: 4148, 2000.
8.
ShaoZ-M, LiJ, WuJ, HanQ-X, ShenZ-Z, FontanaJA, BarskySH. Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis. Br J Cancer Res Treat53: 263269, 1999.
9.
CampbellRA, Bhat-NakshatriP, PatelNM, ConstantinidouD, AliS, NakshatriH. Phosphatidylinositol/3-kinase/Akt-mediated activation of estrogen receptor α: A new model for anti-estrogen receptor resistance. J Biol Chem276: 98179824, 2001.
10.
LevensonAS, JordanCV. MCF-7: The first hormone-responsive breast cancer cell line. Cancer Res57: 30713078, 1997.
11.
SouleHD, VazquezJ, LongA, AlbertS, BrennanM. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst51: 14091416, 1973.
12.
GoochJL, YeeD. Strain-specific differences in formation of apoptotic DNA ladders in MCF-7 breast cancer cells. Cancer Lett144: 3137, 1999.
13.
BurowME, WeldonCB, TangY, NavarGL, KrajewskiS, ReedJC, HammondTG, ClejanS, BeckmanBS. Differences in susceptibility to tumor necrosis factor α-induced apoptosis among MCF-7 breast cancer cell variants. Cancer Res58: 49404946, 1998.
14.
KerrJFR, WyllieAH, CurrieAR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer26: 239257, 1972.
15.
StoryM, KodymR. Signal transduction during apoptosis: Implications for cancer therapy. Frontiers Biosci3: d365d375, 1998.
KaufamnnSH, EarnshawWC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res256: 4249, 2000.
23.
AmeyarM, AtfiA, ZhenziC, StancouR, ShatrovV, BettaiebA, ChouaibS. Analysis of human breast adenocarcinoma MCF-7 resistance to tumor necrosis factor-induced cell death. J Biol Chem273: 2900229008, 1998.
24.
FuldaS, LosM, FriesenC, DebatinK-M. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer76: 105114, 1998.
25.
PoulakiV, MitsiadesCS, MitsiadesN. The role of fas and fasL as mediators of anticancer chemotherapy. Drug Resist Updat4: 233242, 2001.
26.
Ruiz-RuizC, Munoz-PinedoC, Lopez-RivasA. Interferon-γ treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res60: 56735680, 2000.
27.
HerrnringC, ReimerT, JeschkeU, MakovitzkyJ, KrugerK, GerberB, KabelitzD, FrieseK. Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors. Histochem Cell Biol113: 189194, 2000.
28.
ZyadA, BenardJ, TurszT, ClarkeR, ChouaibS. Resistance to TNF-α and adriamycin in the human breast cancer MCF-7 cell line: Relationship to MDR1, MnSOD, and TNF gene expression. Cancer Res54: 825831, 1994.
29.
LongleyDB, BoyerJ, AllenWL, LatifT, FergusonPR, MaxwellPJ, McDermottU, LynchM, HarkinDPThe role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res62: 26442649, 2002.
30.
NakamotoT, IngawaH, TakagiK, SomaG. A new method of antitumor therapy with a high dose of TNF perfusion for nonresectable liver tumors. Anticancer Res20: 40874096, 2000.
31.
KeaneMM, EttenbergSA, NauMM, RussellEK, LipkowitzS. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res59: 734741, 1999.
32.
WallachD, VarfolomeevEE, MalininNL, GoltsevYV, KovalenkoAV, BoldingMP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol17: 331367, 1999.
33.
WallachD. Apoptosis. Placing death under control. Nature388: 123, 125126, 1997.
34.
HuS, VncenzC, NiJ, GentzR, DixitVM. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J Biol Chem272: 1725517257, 1997.
35.
IrmlerM, ThomeM, HahneM, SchneiderP, HofmannK, SteinerV, BodmerJL, SchroterM, BurnsKInhibition of death receptor signals by cellular FLIP. Nature388: 190195, 1997.
36.
EarnshowWC, MartinsLM, KaufmannSH. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem68: 383424, 1999.
37.
DomanRK, PerezM, DantoNJ. JNK and p53 stress signaling cascades are altered in MCF-7 cells resistant to tumor necrosis factor-mediated apoptosis. J Interferon Cytokine Res19: 261269, 1999.
38.
AmeyarM, ShatrovV, BouquetC, CapouladeC, CaiZ, StancouR, BadieC, HaddadaH, ChouaibS. Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: Relationship with c-myc and Rb. Oncogene18: 54645472, 1999.
39.
EgebladM, JaatelaM. Cell death induced by TNF or serum starvation is independent of ErbB receptor signaling in MCF-7 breast carcinoma cells. Int J Cancer86: 617625.
40.
GrossA, McDonnellJM, KorsmeyerSJ. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev13: 18991911, 1999.
41.
HerrI, DebatinK-M. Cellular stress response and apoptosis in cancer therapy. Blood98: 26032614, 2001.
42.
SiemankowskiLM, Morreale, BriehlMM. Antioxidant defenses in TNF-related MCF-7 cells: Selective increase in MnSOD. Free Radic Biol Med26: 919924, 1999.
43.
KurokawaH, KazutoN, FukumotoH, TomonariA, SuzukiT, SaijoN. Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7 breast cancer cells. Oncology Rep6: 3337, 1999.
44.
LiangY, YanC, SchorNF. Apoptosis in the absence of caspase 3. Oncogene20: 65706578, 2001.
45.
JanickeRU, SprengartML, WatiMR, PorterAG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem273: 93579360, 1998.
46.
WolfBB, SchulerM, EcheverriF, GreenDR. Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. J Biol Chem274: 3065130656, 1999.
47.
YangXH, SladekTL, LiuX, ButlerBR, FroelichCJ, ThorAD. Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res61: 348354, 2001.
PettusBJ, ChalfantCE, HannunYA. Ceramide in apoptosis: An overview and current perspectives. Biochim Biophys Acta1585: 114125, 2002.
50.
GudzTI, TserngK-Y, HoppelCL. Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide. J Biol Chem272: 2415424158, 1997.
51.
BasuA, MohantyS, SunB. Differential sensitivity of breast cancer cells to tumor necrosis factor-alpha: Involvement of protein kinase C. Biochem Biophys Res Commun280: 883891, 2001.
52.
SenchenkovA, LitvakDA, CabotMC. Targeting ceramide metabolism: A strategy for overcoming drug resistance. J Natl Cancer Inst93: 347357, 2001.
53.
CaiZ, BettaiebA, El MahdaniN, LegresLC, StancouR, MasliahJ, ChouaibS. Alteration of the sphingomyelin/ceramide pathway is associated with resistance of human breast carcinoma MCF7 cells to tumor necrosis factor-α-mediated cytotoxicity. J Biol Chem272: 69186926, 1997.
54.
LeungLK, WangTTY. Paradoxical regulation of Bcl-2 family proteins by 17β-oestradiol in human breast cancer cells MCF-7. Br J Cancer81: 387392, 1999.
55.
BurowME, TangY, Collins-BurowBM, KrajewskiS, ReedJC, McLachlanJA, BeckmanBS. Effects of environmental estrogens on tumor necrosis factor α-mediated apoptosis in MCF-7 cells. Carcinogenesis20: 20572061, 1999.
56.
VakkalaM, LahteenmakiK, RaunioH, PaakoP, SoiniY. Apoptosis during breast carcinoma progression. Clin Cancer Res5: 319324, 1999.
57.
TudorG, AguileraA, HalversonDO, LiangND, SausvilleEA. Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2, and Bcl-xL protein levels. Cell Death Differ7: 574586, 2000.
58.
LeungLK, WangTTY. Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7. Breast Cancer Res Treat55: 7383, 1999.
59.
GibsonLF, FortneyJ, MagroG, EricsonSG, LynchJP, LandrethKS. Regulation of BAX and BCL-2 expression in breast cancer cells by chemotherapy. Breast Cancer Res Treat55: 107117, 1999.
60.
BerchemGJ, BosselerM, MineN, AvalosseB. Nanomolar range docetaxol treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2. Anticancer Res19: 535540, 1999.
61.
SumantranVN, EalovegaMW, NunezG, ClarkeMF, WichaMS. Overexpression of Bcl-xs sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res55: 25072510, 1995.
62.
PicheA, GrimJ, RancourtC, Gomez-NavarroJ, ReedJC, CurielDT. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res58: 21342140, 1998.
63.
GautschiO, TschoppS, OlieRA, LeechSH, Simoes-WustAP, ZieglerA, BaumannB, OdermattB, HallJ, StahelRA, Zangemeister-WittkeU. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst93: 463471, 2001.
64.
ZhangL, YuJ, ParkBH, KinzlerKW, VogelsteinB. Role of BAX in the apoptotic response to anti-cancer agents. Science290: 989992, 2000.
65.
CamposL, RoualtJP, SabidoO. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood81: 30913096, 1993.
66.
SakakuraC, SweeneyEA, ShirihamaT, IgarashiY, HakomoriS, NakataniH, TsujimotoH, ImanishiT, OhgakiMOverexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int J Cancer67: 101105, 1996.
67.
SuzukiK, TakahashiK. Anchorage-independent activation of mitogen-activated protein kinase through phosphatidylinositol-3 kinase by insulin-like growth factor I. Biochem Biophys Res Commun272: 111115, 2000.
68.
XieW, DuanR, SafeS. Activation of adenosine deaminase in MCF-7 cells through IGF-estrogen receptor alpha crosstalk. J Mol Endocrinol26: 217228, 2001.
69.
RazziniG, BerrieCP, VignatiS, BriginniM, MascettaG, BrancaccioA, FalascaM. Novel function PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines. FASEB J14: 11791187, 2000.
70.
NicholsonKM, AndersonNG. The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal14: 381395, 2002.
71.
GelfanovVM, BurgessGS, Litz-JacksonS, KingAJ, MarshallMS, NakshatriH, BoswellHS. Transformation of interleukin-3-dependent cells without participation of Stat5/bcl-xL: Cooperation of akt with raf/erk leads to p65 nuclear factor κB-mediated antiapoptosis involving c-IAP2. Blood98: 25082517, 2001.
72.
TokerA. Signaling through protein kinase C. Frontiers Biosci3: d1134d1147, 1998.
73.
BurowME, WeldonCB, MelnikLI, DuongBN, Collins-BurowBM, BeckmanBS, McLachlanJA. PI3-K/AKT regulation of NF-κB signaling events in suppression of TNF-induced apoptosis. Biochem Biophys Res Commun271: 342345, 2000.
74.
MengF, LiuL, ChinPC, D'melloSR. AKT is a downstream target of NF-κB. J Biol Chem277: 2967429680, 2002.
75.
BurowME, Collins-BurowBM, WeldonCB, KlippelA, McLachlanJA, ClejanS, BeckmanBS. Cross-talk between phosphatidylinositol 3-kinase and sphingomyelinase pathways as a mechanism for cell survival/death decisions. J Biol Chem275: 96289635, 2000.
LinY, DevinA, RodriguezY, LiuZ-G. Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev13: 25142526, 1999.
78.
Bentires-AljM, DejardinE, ViatourP, Van LintC, FroeschB, ReedJC, MervilleMP, BoursV. Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines. Oncogene20: 805813, 2001.
79.
WeldonCB, BurowME, RolfeKW, ClaytonJL, JaffeBM, BeckmanBS. NF-κB-mediated chemoresistance in breast cancer cells. Surgery130: 143150, 2001.
80.
GuZ, LeeRY, SkaarTC, BoukerKB, WelchJN, LuJ, LiuA, ZhuY, DavisNAssociation of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappa B, and cyclic AMP response element binding with acquired resistance to Fasodex (ICI 182,780). Cancer Res62: 34283437, 2000.
81.
WeldonCB, ScandurroAB, RolfeKW, ClaytonJL, ElliottS, ButlerNN, MelnikLI, AlamJ, McLachlanJAIdentification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery132: 293301, 2002.
